Synergie Medication Collective is an organization composed of the Blue Cross Blue Shield Association, Elevance Health, nine independent BCBS plans and a few other companies. Of the seven cell and gene therapies Synergie prefers, sickle cell treatments Casgevy and Lyfgenia round out the list.
The two drugs are the nation’s first approved CRISPR gene therapies for sickle cell disease, an inherited blood disorder affecting about 100,000 Americans. Casgevy (exagamglogene autotemcel) costs $2.2 million, and Lyfgenia is $3.1 million.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
